Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver

British Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2003, Pages 433-440

  Wilson, Z E ^a   Rostami Hodjegan, A ^a,b   Burn, J L ^a   Tooley, A ^a   Boyle, J ^a   Ellis, S W ^a   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cytochrome P450; In silico ADME; Liver microsomes; Prediction of metabolic clearance; Variability in metabolism

Indexed keywords

LIVER PROTEIN; MICROSOME PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CELLULAR DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CELL; LIVER MICROSOME; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SAMPLE;

ADULT; AGED; ANALYSIS OF VARIANCE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEPATOCYTES; HUMANS; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROTEINS;

EID: 0141839733     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01881.x     Document Type: Article

References (47)

1. Zuegge J, Schneider G, Coassolo P, Lave T. Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin Pharmacokinet 2001; 40: 553-563.
2. Baarnhielm C, Dahlback H, Skanberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol (Copenh) 1986; 59: 113-122.
3. Lipscomb JC, Fisher JW, Confer PD, Byczkowski JZ. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharmacol 1998; 152: 376-387.
4. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999; 47: 625-635.
5. Urata K, Kawasaki S, Matsunami H et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317-1321.
6. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995; 23: 1110-1116.
7. Heinemann A, Wischhusen F, Puschel K, Rogiers X. Standard liver volume in the Caucasian population. Liver Transpl Surg 1999; 5: 366-368.
8. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
9. Andersson TB, Sjoberg H, Hoffmann KJ et al. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 2001; 29: 712-720.
10. Obach RS, Baxter JG, Liston TE et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58.
11. Lipscomb JC, Teuschler LK, Swartout JC, Striley CAF, Snawder JE. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol Mechanisms Meth 2003; 13: 45-51.
12. Ploemen JP, Wormhoudt LW, Haenen GR et al. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. Toxicol Appl Pharmacol 1997; 143: 56-69.
13. Blaauboer BJ, van Holsteijn I, van Graft M, Paine AJ. The concentration of cytochrome P-450 in human hepatocyte culture. Biochem Pharmacol 1985; 34: 2405-2408.
14. Iwatsubo T, Hirota N, Ooie T et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 1997; 282: 909-919.
15. Bayliss MK, Bell JA, Jenner WN, Wilson K. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem Soc Trans 1990; 18: 1198-1199.
16. Arias IM. Introduction., In The Liver: Biology and Pathology., 2nd Edition, eds Arias IM, Popper H, Jakoby WB, Schacter D, Shafritz DA, New York: Raven Press, 1988: 3-10.
17. Cross DM, Bayliss MK. A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metab Rev 2000; 32: 219-240.
18. Hirota N, Ito K, Iwatsubo T et al. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001; 22: 53-71.
19. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998; 38: 461-499.
20. 2+ on enzymatic dispersion of isolated, perfused liver. Exp Cell Res 1972; 74: 450-454.
21. Seglen PO. Preparation of isolated rat liver cells. Meth Cell Biol 1976; 13: 29-83.
22. Guengerich FP. Similarity of nuclear and microsomal cytochromes P-450 in the in vitro activation of aflatoxin B1. Biochem Pharmacol 1979; 28: 2883-2890.
23. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370-2378.
24. Matsubara T, Koike M, Touchi A, Tochino Y, Sugeno K. Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 1976; 75: 596-603.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
26. Smith BR, Bend JR. Prediction of pulmonary benzo(a)pyrene 4,5-oxide clearance: a pharmacokinetic analysis of epoxide-metabolizing enzymes in rabbit lung. J Pharmacol Exp Ther 1980; 214: 478-482.
27. Strobel H, Dignam J. Purification and properties of NADPH-cytochrome P-45 reductase. Meth Enzymol 1978; 52: 91.
28. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
29. Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophysics 1958; 75: 376-386.
30. Paine MJ, Garner AP, Powell D et al. Cloning and characterization of a novel human dual flavin reductase. J Biol Chem 2000; 275: 1471-1478.
31. von Bahr C, Groth CG, Jansson H et al. Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 1980; 27: 711-725.
32. Shaw L, Lennard MS, Tucker GT, Bax ND, Woods HF. Irreversible binding and metabolism of propranolol by human liver microsomes - relationship to polymorphic oxidation. Biochem Pharmacol 1987; 36: 2283-2288.
33. Powis G, Jardine I, Van Dyke R et al. Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage. Drug Metab Dispos 1988; 16: 582-589.
34. Schmucker DL, Woodhouse KW, Wang RK et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-374.
35. Pearce RE, McIntyre CJ, Madan A et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996; 331: 145-169.
36. Grant MH, Burke MD, Hawksworth GM et al. Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochem Pharmacol 1987; 36: 2311-2316.
37. Seddon T, Michelle I, Chenery RJ. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem Pharmacol 1989; 38: 1657-1665.
38. Robson RA, Matthews AP, Miners JO et al. Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol 1987; 24: 293-300.
39. Richard B, Fabre G, De Sousa G et al. Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. Biochem Pharmacol 1991; 41: 255-262.
40. Griese EU, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26.
41. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
42. Shimoda K, Someya T, Morita S et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 261-265.
43. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
44. Eggens I, Backman L, Jakobsson A, Valtersson C. The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids. Br J Exp Pathol 1988; 69: 671-683.
45. Hamamoto I, Tanaka S, Maeba T, Chikaishi K, Ichikawa Y. Microsomal cytochrome P-450-linked monooxygenase systems and lipid composition of human hepatocellular carcinoma. Br J Cancer 1989; 59: 6-11.
46. Sumner IG, Lodola A. Total cytochrome P-450, but not the major phenobarbitone or 3-methylcholanthrene induced isoenzyme, is differentially induced in the lobes of the rat liver. Biochem Pharmacol 1987; 36: 391-393.
47. Watkins PB, Murray SA, Thomas PE, Wrighton SA. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. Biochem Pharmacol 1990; 39: 471-476.